Vilon: what it is and what the evidence says
A dipeptide from the Russian bioregulator school. It is proposed to work by regulating gene expression in specific tissues.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Two very different things live under the same label here: serious research into mitochondria, cellular senescence and DNA repair, and a market of promises built on studies that were never replicated. Telling them apart is most of the work, and this is the area where it matters most to look at who signed each study.
What it is studied for
Advertised for immunity and longevity.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
Its group of origin reports small clinical studies in Russia: 150 people with type 1 diabetes, 63 surgical patients in a design described as randomized and double-blind, and more than 250 adults aged 65 to 87 with chronic periodontitis, with changes in immune and coagulation markers. There are also ex vivo studies on lymphocytes from people aged 75 to 88.
The limitation that matters most
Nearly all of the literature comes from the same school and was published in Russian, without replication by independent groups. Large placebo-controlled trials, human pharmacokinetics and long-term safety follow-up are still missing.
Regulatory status
It is not approved by the FDA or the EMA. In Russia it received permission for clinical trials in 2002, and no record of registration as a medicine was found. It is not listed by name on the 2026 WADA Prohibited List; anyone who competes under anti-doping control should confirm with their federation whether category S0, for substances without health-authority approval, applies.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
No independent replication. No pharmacokinetic data to explain the proposed mechanism.
With recurrent infections, autoimmune disease, a transplant, active cancer, pregnancy or breastfeeding, have a professional assess it before you start.
What this page cannot give you
A reference page can take you this far. You know what Vilon is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]review Adv Gerontol · 2013 · PMID 24003726 →
- Effects of short peptides on lymphocyte chromatin in senile subjectshuman Bull Exp Biol Med · 2004 · PMID 15085253 →
- Anti-aging peptide bioregulators induce reactivation of chromatinhuman Georgian Med News · 2006 · PMID 16705247 →
- Tissue-specific effects of peptidespreclinical Bull Exp Biol Med · 2001 · PMID 11713572 →
- [Biological activity of regulatory peptides in model experiments in vitro]preclinical Adv Gerontol · 2008 · PMID 18546826 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Vilon or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Vilon?
A dipeptide from the Russian bioregulator school. It is proposed to work by regulating gene expression in specific tissues. It is studied within the area of longevity/cellular.
Is there human evidence for Vilon?
Its group of origin reports small clinical studies in Russia: 150 people with type 1 diabetes, 63 surgical patients in a design described as randomized and double-blind, and more than 250 adults aged 65 to 87 with chronic periodontitis, with changes in immune and coagulation markers. There are also ex vivo studies on lymphocytes from people aged 75 to 88.
Is it approved by any health agency?
It is not approved by the FDA or the EMA. In Russia it received permission for clinical trials in 2002, and no record of registration as a medicine was found. It is not listed by name on the 2026 WADA Prohibited List; anyone who competes under anti-doping control should confirm with their federation whether category S0, for substances without health-authority approval, applies.
What is the dose of Vilon?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Vilon is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.